Which phenotypic and molecular characteristics predict differential responses to therapy in individuals with chronic heart, lung, blood, and sleep (HLBS) diseases?
There is a need to create tools to access and analyze electronic medical records (EMR) data and its linkage to “omics.”
There is a need to develop hand-held portable imaging or other technologies that can help paramedics to collect and transmit data when patients are undergoing cardiovascular events.
How do we enable technologies that improve the precision and depth by which we evaluate patients to better understand pathophysiology and develop, test and optimize therapy?
Use of EHR to understand HLB disease?
Should NHLBI/researchers have a larger role in the development of the EHR?
Can we extend gene editing and iPS/cell technologies to high throughput formats for the evaluation of genetic variants identified from GWAS in the development and progression of disease?
How can NHLBI harness the power of novel technologies involving nucleic acid delivery and gene editing for clinical therapeutics?